Treatment Options for KRASG12C Mutated NSCLC

Opinion
Video

Dr Narjust Florez outlines FDA-approved firstline therapy options for KRAS G12C mutated non-small cell lung cancer, and notes most patients progress and require second line targeted therapy.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
4 experts in this video
Related Content
The decision from the Ministry of Health, Labour, and Welfare was supported by phase 3 LUNAR trial results showing an OS benefit with Optune Lua in NSCLC.

TTFields Earns Japanese Approval in Unresectable Advanced/Recurrent NSCLC

Roman Fabbricatore
September 17th 2025
Article
Jacob Sands, MD, discussed considerations for EGFR-mutant non–small cell lung cancer following the approval of dato-DXd in this disease.

Integrating Dato-DXd Into Early-Line EGFR-Mutant NSCLC Management

Jacob Sands, MD
September 17th 2025
Podcast
A subgroup analysis of OS showed that results were favorable with amivantamab plus lazertinib in patients who are Asian.

Amivantamab Combo Significantly Improves OS in Asian EGFR+ NSCLC Population

Tim Cortese
September 17th 2025
Article
Stephen Liu, MD, and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

Practice-Changing Lung Cancer Data From the 2025 ASCO Annual Meeting

Stephen V. Liu, MD;Joshua K. Sabari, MD
September 17th 2025
Podcast
Crizotinib Falls Short on DFS and OS Improvements in ALK+ NSCLC

Crizotinib Falls Short on DFS and OS Improvements in ALK+ NSCLC

Jax DiEugenio
September 17th 2025
Article
Frontline Aumolertinib/Chemo Yields PFS Superiority in EGFR+ NSCLC

Frontline Aumolertinib/Chemo Yields PFS Superiority in EGFR+ NSCLC

Jax DiEugenio
September 17th 2025
Article